Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone

Contraception. 2006 Dec;74(6):451-7. doi: 10.1016/j.contraception.2006.07.004. Epub 2006 Sep 27.

Abstract

Purpose: This randomized multicenter, open-label, trial compared efficacy, acceptability, tolerability and compliance of NuvaRing with a combined oral contraceptive (COC), containing 30 microg of ethinyl estradiol (EE) and 3 mg of drospirenone.

Method: In this 13-cycle study, 983 women were randomized and treated (intent-to-treat population) with NuvaRing or COC.

Results: One in-treatment pregnancy occurred with NuvaRing (Pearl Index=0.25) (95% confidence interval [CI]: 0.006, 1.363) and four with the COC (Pearl Index=0.99) (95% CI: 0.269, 2.530). For both groups, compliance (89.2% NuvaRing, 85.5% COC) and satisfaction (84% NuvaRing; 87% COC) were high; the vast majority of women found NuvaRing easy to insert (96%) and remove (97%). Tolerability was similar; the most frequent adverse events with NuvaRing were related to ring use, whereas estrogen-related events were more common with the COC.

Conclusion: NuvaRing has comparable efficacy and tolerability to a COC containing 30 microg of EE and 3 mg drospirenone. User acceptability of both methods was high.

Publication types

  • Clinical Trial, Phase III
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Androstenes / administration & dosage*
  • Androstenes / adverse effects
  • Contraception
  • Contraceptive Agents / administration & dosage
  • Contraceptive Agents / adverse effects
  • Contraceptives, Oral, Combined / administration & dosage
  • Contraceptives, Oral, Combined / adverse effects
  • Desogestrel / administration & dosage
  • Desogestrel / adverse effects
  • Desogestrel / analogs & derivatives
  • Drug Combinations
  • Ethinyl Estradiol / administration & dosage*
  • Ethinyl Estradiol / adverse effects
  • Female
  • Humans
  • Intrauterine Devices* / adverse effects
  • Patient Compliance
  • Patient Satisfaction
  • Pregnancy
  • Progesterone Congeners / administration & dosage
  • Progesterone Congeners / adverse effects
  • Treatment Outcome

Substances

  • Androstenes
  • Contraceptive Agents
  • Contraceptives, Oral, Combined
  • Drug Combinations
  • NuvaRing
  • Progesterone Congeners
  • Ethinyl Estradiol
  • Desogestrel
  • drospirenone